Johnson & Johnson reported third-quarter 2026 sales up 5.9% to $25.4 billion, but net earnings fell 95.9% to $210 million after a one-time special charge for the proposed talc litigation resolution. Adjusted EPS fell 7.5% to $2.59, and the company raised its full-year 2026 adjusted EPS guidance midpoint to $11.10, which matters to shareholders because the higher outlook is offset by a large reported charge and lower adjusted profit.
Q3 2026 reported sales were $25,399 million, up 5.9% from $23,993 million; net earnings were $210 million versus $5,152 million, and diluted EPS was $0.09 versus $2.12.
Adjusted diluted EPS was $2.59 versus $2.80 a year earlier, down 7.5%.
Full-year 2026 adjusted EPS guidance midpoint rose to $11.10 from $11.04 in July 2026; estimated reported sales midpoint is $101.2 billion.
Other (income) expense, net was $5,780 million in the quarter, reflecting the talc litigation charge, the Firefly Bio acquisition and the Sail Biomedicines collaboration.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Johnson & Johnson's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$94.19B
+6.0%
$11.03
+90.5%
28.5%
FY2024
$88.82B
+4.3%
$5.79
-57.8%
15.8%
FY2023
$85.16B
+6.5%
$13.72
+103.9%
41.3%
FY2023
$79.99B
+1.6%
$6.73
-13.8%
22.4%
FY2022
$78.74B
-4.7%
$7.81
+41.7%
26.5%
Frequently asked questions
When is Johnson & Johnson's next earnings date?
Johnson & Johnson has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Johnson & Johnson earn last quarter?
For the quarter ended Sep 2026, Johnson & Johnson reported diluted EPS of $0.09 (-95.8% year over year) on revenue of $25.40B (+5.9%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.